Arcturus Therapeutics develops messenger RNA medicines and vaccines using its LUNAR lipid-mediated delivery and STARR self-amplifying mRNA technologies. It has commercialized KOSTAIVE, the world's first approved self-amplifying mRNA COVID-19 vaccine, and advances candidates for rare diseases such as cystic fibrosis and ornithine transcarbamylase deficiency. The company collaborates on additional mRNA vaccine programs and maintains in-house manufacturing expertise.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 24.5 | — | -9.2 | — |
| Q3 2025 | 14.2 | — | -13.4 | — |
| Q4 2025 | 3.1 | — | -29.1 | — |
| Q1 2026 | 0.6 | — | -27 | — |
| Q2 2026 | 0.9 | -96.4% | -23.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Horizon Technology Finance Corporation (HRZN), ACP Holdings Acquisition Corp. (ACGC), Friedman Industries, Incorporated (FRD), Blue Acquisition Corp. (BACC), Launchpad Cadenza Acquisition Corp I (LPCV), Lands' End, Inc. (LE)